CL2016000820A1 - Diagnóstico y tratamiento del síndrome del intestino irritable y la enfermedad inflamatoria intestinal - Google Patents

Diagnóstico y tratamiento del síndrome del intestino irritable y la enfermedad inflamatoria intestinal

Info

Publication number
CL2016000820A1
CL2016000820A1 CL2016000820A CL2016000820A CL2016000820A1 CL 2016000820 A1 CL2016000820 A1 CL 2016000820A1 CL 2016000820 A CL2016000820 A CL 2016000820A CL 2016000820 A CL2016000820 A CL 2016000820A CL 2016000820 A1 CL2016000820 A1 CL 2016000820A1
Authority
CL
Chile
Prior art keywords
diagnosis
treatment
inflammatory bowel
bowel disease
bowel syndrome
Prior art date
Application number
CL2016000820A
Other languages
English (en)
Spanish (es)
Inventor
Mark Pimentel
Christopher Chang
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000820(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of CL2016000820A1 publication Critical patent/CL2016000820A1/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ecology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CL2016000820A 2013-10-09 2016-04-08 Diagnóstico y tratamiento del síndrome del intestino irritable y la enfermedad inflamatoria intestinal CL2016000820A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361888658P 2013-10-09 2013-10-09

Publications (1)

Publication Number Publication Date
CL2016000820A1 true CL2016000820A1 (es) 2016-09-23

Family

ID=52813648

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000820A CL2016000820A1 (es) 2013-10-09 2016-04-08 Diagnóstico y tratamiento del síndrome del intestino irritable y la enfermedad inflamatoria intestinal

Country Status (19)

Country Link
US (2) US9851361B2 (enExample)
EP (1) EP3054977B1 (enExample)
JP (1) JP6567509B2 (enExample)
KR (1) KR102259588B1 (enExample)
CN (1) CN105744956B (enExample)
AU (2) AU2014331841B2 (enExample)
BR (1) BR112016007474A2 (enExample)
CA (1) CA2923651C (enExample)
CL (1) CL2016000820A1 (enExample)
ES (1) ES2892905T3 (enExample)
IL (1) IL244971B2 (enExample)
MX (1) MX383423B (enExample)
NZ (1) NZ717633A (enExample)
PE (1) PE20160882A1 (enExample)
PL (1) PL3054977T3 (enExample)
PT (1) PT3054977T (enExample)
RU (1) RU2683781C2 (enExample)
SG (1) SG11201601733VA (enExample)
WO (1) WO2015054529A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9851361B2 (en) 2013-10-09 2017-12-26 Cedars-Sinai Medical Center Methods of comparing anti-vinculin and anti-cytolethal distending toxin antibodies as they relate to irritable bowel syndrome
US9869676B2 (en) 2009-02-11 2018-01-16 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US9952223B2 (en) 2012-09-17 2018-04-24 Cedars-Sinai Medical Center Method for detecting anti-vinculin antibodies in a subject with an IBS symptom
US10132814B2 (en) 2014-10-09 2018-11-20 Cedars-Sinai Medical Center Methods for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106053827A (zh) * 2016-05-17 2016-10-26 上海凯璟生物科技有限公司 一种肠易激综合症标志物Vinculin抗体检测试剂盒及其制备方法
CN105784989A (zh) * 2016-05-17 2016-07-20 上海凯璟生物科技有限公司 一种肠易激综合症标志物CdtB抗体检测试剂盒及其制备方法
WO2017201461A1 (en) 2016-05-20 2017-11-23 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease based on genes
RU2763258C1 (ru) * 2020-07-13 2021-12-28 Евгения Николаевна Воронина Способ дифференциальной диагностики воспалительных заболеваний кишечника у детей по комплексу клинико-анамнестических, лабораторных и инструментальных критериев

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
FR2806805A1 (fr) 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
WO2003097854A2 (en) * 2002-05-17 2003-11-27 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
JP2006515165A (ja) 2002-09-16 2006-05-25 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
US7595386B2 (en) 2003-01-24 2009-09-29 William Beaumont Hospital Methods and compositions for heat activated gene therapy using cytolethal distending toxin
BRPI0409128A (pt) * 2003-04-08 2006-03-28 Progenics Pharm Inc uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável
EP1664796B1 (en) * 2003-09-15 2010-12-15 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate ankylosing spondylitis
KR101152078B1 (ko) 2003-12-05 2012-06-21 후소 야쿠힝 고교 가부시끼가이샤 세포팽창화 치사독 및 그것을 표적으로 한 캄필로박터속에속하는 세균의 검출
EP2102367A2 (en) 2006-11-09 2009-09-23 XDX, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
DK2223121T3 (da) 2007-12-20 2012-10-22 Index Diagnostics Ab Publ Fremgangsmåde og kit til anvendelse ved differentiering mellem ibd og ibs og yderligere skelnen mellem ibd-sygdomstyper
ES2529060T3 (es) 2008-11-24 2015-02-16 Cedars-Sinai Medical Center Derivados antioxidantes de la camptotecina y nanoesferas antineoplásicas antioxidantes de los mismos
MX2011008354A (es) 2009-02-11 2011-09-06 Cedars Sinai Medical Center Terapia antibiotica para reducir la probabilidad de desarrollar el sindrome del intestino irritable post-infeccioso.
CA2752033C (en) 2009-02-11 2020-03-24 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of campylobacter jejuni
FR2942541A1 (fr) 2009-02-25 2010-08-27 Assist Publ Hopitaux De Paris Procede de diagnostic d'une vascularite
RU2397178C1 (ru) * 2009-02-27 2010-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса
IT1400989B1 (it) 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
GB201017520D0 (en) 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
ES2646598T3 (es) 2012-09-17 2017-12-14 Cedars-Sinai Medical Center Diagnóstico y tratamiento de los trastornos de la motilidad del intestino y la vejiga, y de la fibromialgia
AU2014331841B2 (en) 2013-10-09 2020-03-12 Cedars-Sinai Medical Center Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease
MX384921B (es) 2014-10-09 2025-03-14 Cedars Sinai Medical Center Métodos y sistemas para distinguir el síndrome del intestino irritable de la enfermedad inflamatoria intestinal y la enfermedad celíaca.
CN106091069A (zh) 2016-06-15 2016-11-09 安徽省绿巨人环境技术有限公司 一种废水再利用装置
JP2020507755A (ja) 2017-01-30 2020-03-12 シーダーズ−サイナイ メディカル センター 強皮症の診断法

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9869676B2 (en) 2009-02-11 2018-01-16 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US10151752B2 (en) 2009-02-11 2018-12-11 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US10527621B2 (en) 2009-02-11 2020-01-07 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
US9952223B2 (en) 2012-09-17 2018-04-24 Cedars-Sinai Medical Center Method for detecting anti-vinculin antibodies in a subject with an IBS symptom
US10466254B2 (en) 2012-09-17 2019-11-05 Cedars-Sinai Medical Center Method of measuring a level of anti-vinculin antibodies in a biological sample
US9851361B2 (en) 2013-10-09 2017-12-26 Cedars-Sinai Medical Center Methods of comparing anti-vinculin and anti-cytolethal distending toxin antibodies as they relate to irritable bowel syndrome
US10352944B2 (en) 2013-10-09 2019-07-16 Cedars-Sinai Medical Center Method of determinig levels of anti-vinculin and anti-cytolethal distending toxin antibodies in subjects desiring to distinguish irritable bowel syndrome from inflammatory bowel disease
US10132814B2 (en) 2014-10-09 2018-11-20 Cedars-Sinai Medical Center Methods for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
US10690679B2 (en) 2014-10-09 2020-06-23 Cedars-Sinai Medical Center Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Also Published As

Publication number Publication date
RU2016116766A (ru) 2017-11-15
EP3054977A1 (en) 2016-08-17
IL244971A0 (en) 2016-05-31
HK1221898A1 (zh) 2017-06-16
EP3054977A4 (en) 2017-04-12
JP2017502253A (ja) 2017-01-19
EP3054977B1 (en) 2021-07-21
US20170038393A1 (en) 2017-02-09
KR102259588B1 (ko) 2021-06-02
US9851361B2 (en) 2017-12-26
CA2923651A1 (en) 2015-04-16
IL244971B1 (en) 2023-08-01
AU2020203468A1 (en) 2020-06-18
NZ717633A (en) 2021-07-30
CN105744956A (zh) 2016-07-06
MX2016004167A (es) 2016-06-24
PT3054977T (pt) 2021-10-14
ES2892905T3 (es) 2022-02-07
AU2014331841A1 (en) 2016-03-24
CA2923651C (en) 2023-03-14
US20180196063A1 (en) 2018-07-12
PE20160882A1 (es) 2016-09-14
BR112016007474A2 (pt) 2017-09-12
KR20160062161A (ko) 2016-06-01
AU2014331841B2 (en) 2020-03-12
JP6567509B2 (ja) 2019-08-28
CN105744956B (zh) 2021-07-20
PL3054977T3 (pl) 2021-12-20
WO2015054529A1 (en) 2015-04-16
US10352944B2 (en) 2019-07-16
MX383423B (es) 2025-03-14
SG11201601733VA (en) 2016-04-28
RU2683781C2 (ru) 2019-04-02
IL244971B2 (en) 2023-12-01

Similar Documents

Publication Publication Date Title
CL2016000820A1 (es) Diagnóstico y tratamiento del síndrome del intestino irritable y la enfermedad inflamatoria intestinal
EP2968397A4 (en) DIAGNOSIS AND TREATMENT OF FIBROSIS
EP2971127A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT OF INFLAMMABLE ENDURANCE
EP2890806A4 (en) PROCESSING BIOMASS
HUE049569T2 (hu) Immunrendszerrel kapcsolatos és gyulladásos megbetegedések kezelése
EP2968208A4 (en) TREATMENT OF CATAPLEXIA
EP2882496A4 (en) TREATMENT AND DIAGNOSIS OF MELANOMA
EP3307329A4 (en) CANCER TREATMENT AND DIAGNOSIS
EP2995263A4 (en) ENDOSCOPIC TREATMENT INSTRUMENT
IL240509B (en) Fluorescence imaging of inflammatory diseases
EP3011515A4 (en) LANGUAGE TRANSACTION PROCESSING
EP2948188A4 (en) NEURAL IMAGING AND TREATMENT
LT4000608T (lt) Farmacinė kompozicija, gydymo būdai ir jų panaudojimas
EP2890815A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP2903691A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT OF INFLAMMABLE ENDURANCE
PT3626270T (pt) Tratamento de doenças cardiovasculares
EP2890804A4 (en) PROCESSING BIOMASS
CO7020918A2 (es) Señalización de slit-robo para diagnosis y tratamiento de enfermedad del riñón
EP2995262A4 (en) ENDOSCOPIC TREATMENT INSTRUMENT
IL275368B (en) Diagnosis and treatment of autoimmune diseases
HUE050485T2 (hu) Tauopathia kezelési módszerei
EP3458466A4 (en) DIAGNOSIS OF INFLAMMATORY COLON DISEASE BASED ON GENES
EP2945616A4 (en) TREATMENT OF LUNG DISEASES
LT2958624T (lt) Transplantuotų pacientų transplantanto prieš šeiminiką ligos gydymas
IT1402047B1 (it) Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali